DBV TECHNOLOGIE/S (NASDAQ:DBVT) and BIONDVAX PHARMA/S (NASDAQ:BVXV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Insider & Institutional Ownership
45.4% of DBV TECHNOLOGIE/S shares are owned by institutional investors. Comparatively, 6.9% of BIONDVAX PHARMA/S shares are owned by institutional investors. 15.3% of DBV TECHNOLOGIE/S shares are owned by company insiders. Comparatively, 6.0% of BIONDVAX PHARMA/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares DBV TECHNOLOGIE/S and BIONDVAX PHARMA/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares DBV TECHNOLOGIE/S and BIONDVAX PHARMA/S’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DBV TECHNOLOGIE/S||$13.45 million||59.54||-$166.93 million||($3.37)||-4.17|
|BIONDVAX PHARMA/S||N/A||N/A||-$9.96 million||($1.98)||-2.86|
BIONDVAX PHARMA/S has lower revenue, but higher earnings than DBV TECHNOLOGIE/S. DBV TECHNOLOGIE/S is trading at a lower price-to-earnings ratio than BIONDVAX PHARMA/S, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and recommmendations for DBV TECHNOLOGIE/S and BIONDVAX PHARMA/S, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DBV TECHNOLOGIE/S presently has a consensus target price of $36.40, indicating a potential upside of 159.26%. Given DBV TECHNOLOGIE/S’s higher possible upside, analysts plainly believe DBV TECHNOLOGIE/S is more favorable than BIONDVAX PHARMA/S.
Risk & Volatility
DBV TECHNOLOGIE/S has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
DBV TECHNOLOGIE/S beats BIONDVAX PHARMA/S on 8 of the 11 factors compared between the two stocks.
About DBV TECHNOLOGIE/S
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
About BIONDVAX PHARMA/S
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.